OK, how you read or misread what I posted should not be the issue here. All I meant to say was that the redefining by the WHO of GBM, should be neither here nor there in regards to the success or failure of the PIII trial. It should stand or fall on what it intended to show and what was actually found about those in the trial. Any latter day relabeling should have no effect on the outcome of the trial either way. It would be like doing some gravity testing on Pluto before it was reclassified not to be a planet. The relabel should not affect the trial. So if someone was admitted to the trial under its stated terms, the fact that he was now relabeled to some other disease, other than GBM, should bot change anything. This has nothing to do with NWBO trying to do anything. The only thing that happened, was that in some distant land, a new label definition was being applied to some who happened to be in the NWBO trial. This should leave the trial totally unchanged and should succeed or fail on its own terms.
Market Data 
Markets 
AI
